Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study

Abacavir use and risk of recurrent myocardial infarction

(2018) Caroline A. Sabin et al.   AIDS

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

(2018) Barbara Rossetti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection

(2018) Pedro Cahn et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART

(2018) A Nouchi et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

(2018) Lene Ryom et al.   Lancet HIV

HIV

(2018) Jade Ghosn et al.   LANCET

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Association of Macrophage Inflammation Biomarkers With Progression of Subclinical Carotid Artery Atherosclerosis in HIV-Infected Women and Men

(2017) David B. Hanna et al.   JOURNAL OF INFECTIOUS DISEASES

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s

(2016) Grace A. McComsey et al.   CLINICAL INFECTIOUS DISEASES

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

(2016) Anthony Mills et al.   LANCET INFECTIOUS DISEASES

Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study

(2016) Mariam Noelie Hema et al.   PLoS One

Future challenges for clinical care of an ageing population infected with HIV: a modelling study

(2015) Mikaela Smit et al.   LANCET INFECTIOUS DISEASES

Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: a nationwide population-based cohort study

(2015) Line D Rasmussen et al.   Lancet HIV

Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study

(2014) J. Schouten et al.   CLINICAL INFECTIOUS DISEASES

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

(2014) François Raffi et al.   LANCET

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial

(2014) Pedro Cahn et al.   LANCET INFECTIOUS DISEASES

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study

(2013) P. Monteiro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Novel Method To Assess Antiretroviral Target Trough Concentrations UsingIn VitroSusceptibility Data

(2012) Edward P. Acosta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy

(2012) Ruxandra Calin et al.   ANTIVIRAL THERAPY

Predictors of Clinically Significant Drug-Drug Interactions Among Patients Treated with Nonnucleoside Reverse Transcriptase Inhibitor–, Protease Inhibitor–, and Raltegravir-Based Antiretroviral Regimens

(2011) Nimish Patel et al.   ANNALS OF PHARMACOTHERAPY

Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population

(2011) G. Guaraldi et al.   CLINICAL INFECTIOUS DISEASES

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia

(2011) M. Wirden et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection

(2011) Netanya G. Sandler et al.   JOURNAL OF INFECTIOUS DISEASES

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

(2010) Esteban Martinez et al.   AIDS

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

(2010) Christine Katlama et al.   ANTIVIRAL THERAPY

Greater Tenofovir‐Associated Renal Function Decline with Protease Inhibitor–Based versus Nonnucleoside Reverse‐Transcriptase Inhibitor–Based Therapy

(2007) Miguel Goicoechea et al.   JOURNAL OF INFECTIOUS DISEASES